Abzena consolidates UK and West Coast USA operations into two single facilities. Abzena has entered into a preferred biomanufacturing equipment supply and services agreement to supply the bioprocess reactor equipment, process analytic software and to provide support for the design of the new biomanufacturing facility in San Diego.
In Cambridge, UK, the Group’s lease has commenced for 30,000 square feet of space in Building 900 on the Babraham Research Campus. The Group has also entered into an agreement with BBT to run and develop the antibody discovery services formerly provided by BBT’s Technology Development Laboratory. The new building has been purpose-built to accommodate Abzena’s needs and enables all the Group’s UK-based science teams to work together in a single, state-of-the-art facility.
Abzena has negotiated and now concluded a lease for a 50,000 square feet facility at Lusk Boulevard, San Diego to consolidate the West Coast biomanufacturing operations into a single state of the art facility. The facility is expected to be fully operational from early 2019.
John Burt, CEO of Abzena, commented:
“The new facilities in Cambridge and San Diego are an important strategic step in the delivery of our integrated services model and will greatly enhance Abzena’s operations. The combination of state-of-the-art facilities and leading technologies will enable the Group to support its international customers as they progress their drug development programs from research into clinical trials.”